Discovers and develops small molecule drugs for various diseases. Commercializes Tavalisse (fostamatinib) for adult patients with chronic immune thrombocytopenia (ITP). Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 19% a year over the last 4 years. Red columns mark years that ended in a loss.
The market pays 2.4× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
Against companies in its own sector, it looks cheaper than 84% of them.
Analysts' average target sits 41% above today's price.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
The cash pile is strong; debt and other items pull the grade toward the middle.
The price looks reasonable next to what the company earns.
Sales are growing strongly for its sector.
The stock has been running stronger than the market lately.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 19% a year on average.
There is $155.0M in the vault; even if every debt were paid off, $101.7M would remain.
Our checks did not surface a specific risk to flag here. That is not the same as there being none.
On our five-subject report card, RIGL sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: RIGL is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.